Pacer Advisors Inc. boosted its position in Doximity, Inc. (NASDAQ:DOCS – Free Report) by 167.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 297,132 shares of the company’s stock after acquiring an additional 186,093 shares during the quarter. Pacer Advisors Inc. owned 0.16% of Doximity worth $15,864,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other large investors have also added to or reduced their stakes in DOCS. FMR LLC increased its position in shares of Doximity by 30.5% during the 3rd quarter. FMR LLC now owns 6,837,733 shares of the company’s stock valued at $297,920,000 after purchasing an additional 1,598,602 shares during the last quarter. Clearbridge Investments LLC lifted its position in Doximity by 7.1% in the second quarter. Clearbridge Investments LLC now owns 5,853,035 shares of the company’s stock valued at $163,709,000 after purchasing an additional 387,200 shares during the last quarter. State Street Corp boosted its stake in shares of Doximity by 2.5% during the third quarter. State Street Corp now owns 3,693,982 shares of the company’s stock valued at $160,947,000 after purchasing an additional 88,922 shares during the period. Geode Capital Management LLC grew its holdings in Doximity by 19.8% in the 3rd quarter. Geode Capital Management LLC now owns 2,856,984 shares of the company’s stock worth $124,503,000 after acquiring an additional 472,565 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its position in shares of Doximity by 28.5% in the second quarter. Dimensional Fund Advisors LP now owns 1,267,067 shares of the company’s stock valued at $35,439,000 after acquiring an additional 281,239 shares during the period. Hedge funds and other institutional investors own 87.19% of the company’s stock.
Analyst Ratings Changes
Several research firms recently issued reports on DOCS. Barclays raised their target price on Doximity from $52.00 to $75.00 and gave the stock an “overweight” rating in a research note on Monday, November 11th. The Goldman Sachs Group started coverage on shares of Doximity in a report on Friday, November 15th. They issued a “neutral” rating and a $58.00 price objective for the company. Morgan Stanley upgraded Doximity from an “underweight” rating to an “equal weight” rating and upped their target price for the stock from $33.00 to $53.00 in a report on Thursday, November 14th. Evercore ISI raised their target price on Doximity from $34.00 to $45.00 and gave the company an “in-line” rating in a research note on Tuesday, October 8th. Finally, Wells Fargo & Company upped their price target on Doximity from $41.00 to $43.00 and gave the stock an “equal weight” rating in a research note on Monday, January 13th. Thirteen analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $53.12.
Doximity Stock Performance
DOCS opened at $57.17 on Wednesday. The company’s 50-day simple moving average is $53.98 and its two-hundred day simple moving average is $44.06. Doximity, Inc. has a 52-week low of $22.96 and a 52-week high of $61.75. The stock has a market capitalization of $10.67 billion, a P/E ratio of 65.71, a P/E/G ratio of 4.43 and a beta of 1.38.
Doximity (NASDAQ:DOCS – Get Free Report) last posted its earnings results on Thursday, November 7th. The company reported $0.24 EPS for the quarter, missing analysts’ consensus estimates of $0.26 by ($0.02). The company had revenue of $136.83 million during the quarter, compared to the consensus estimate of $127.05 million. Doximity had a return on equity of 19.79% and a net margin of 33.69%. During the same period last year, the firm posted $0.18 EPS. Research analysts forecast that Doximity, Inc. will post 0.88 EPS for the current fiscal year.
Doximity Profile
Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.
See Also
- Five stocks we like better than Doximity
- How to Plot Fibonacci Price Inflection Levels
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- What Does the Future Hold for Eli Lilly?
- 3 Stocks to Consider Buying in October
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Receive News & Ratings for Doximity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Doximity and related companies with MarketBeat.com's FREE daily email newsletter.